Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Matthew Sarb

Orthopaedic Surgery Dickson, TN Doctor of Osteopathy

NPI 1407045230 CMS profile 244557

127 Crestview Park Dr Ste 204, Dickson, TN 37055

Open in the dashboard

General payments

$5,308

102 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Matthew Sarb of Dickson, TN is reported in the CMS Open Payments database as having received $5,308 across 102 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 57th percentile of Orthopaedic Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,537 24
2024 General $422 21
2023 General $305 13
2022 General $506 17
2021 General $162 10
2020 General $138 4
2019 General $2,239 13

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Matthew Sarb
  • Orthopaedic Surgery median
  • Middle half of Orthopaedic Surgery
  • National median

In program year 2025, general payments to Matthew Sarb were reported at $1,537. Among 15,343 Orthopaedic Surgery profiles paid that year, the median was $563 and the middle half received between $147 and $2,717.

Show as a table
Year Matthew Sarb Orthopaedic Surgery median Middle half National median
2019 $2,239 $644 $140–$2,844 $163
2020 $138 $312 $75–$1,860 $114
2021 $162 $520 $117–$2,495 $132
2022 $506 $598 $128–$2,731 $149
2023 $305 $461 $128–$2,264 $160
2024 $422 $497 $134–$2,475 $164
2025 $1,537 $563 $147–$2,717 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Encore Medical, LP $2,043 3 payments
  2. Ortho Development Corporation $1,049 4 payments
  3. Amgen Inc. $334 18 payments
  4. Alpha Orthopedic Systems $182 3 payments
  5. Endo Pharmaceuticals Inc. $155 9 payments
  6. Flexion Therapeutics, Inc. $152 8 payments
  7. Smith+Nephew, Inc. $142 5 payments
  8. Stryker Corporation $101 5 payments
  9. Vertex Pharmaceuticals Incorporated $95 3 payments
  10. Arthrosurface Incorporated $92 1 payment
  11. Other $963 43 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $2,358 98 payments
  2. Honoraria $1,500 1 payment
  3. Travel and Lodging $1,450 3 payments
Products named General payments · program years 2019–2025
  1. DJO Surgical Empowr Knee System $1,500 1 payment
  2. DJO Surgical TaperFill Hip System $1,500 1 payment
  3. DJO Surgical Exprt Revision Hip $1,500 1 payment
  4. BKS TriMax $1,049 4 payments
  5. Balanced Knee System $1,049 4 payments
  6. DJO Surgical 3DKnee System $517 1 payment
  7. EVENITY $285 16 payments
  8. XIAFLEX $243 13 payments
  9. Prolia $222 13 payments
  10. Zilretta $152 8 payments
  11. Other $2,050 67 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 15 drugs

Part D claims

2,103

Median for Orthopedic Surgery: 203

Drug cost

$20,921

Median for Orthopedic Surgery: $1,433

Branded share of claims

8.9%

Median for Orthopedic Surgery: 11.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Xarelto Rivaroxaban Brand 13 $7,247
Celecoxib Generic 553 $6,260
Meloxicam Generic 929 $2,390
Methylprednisolone Generic 180 $1,292
Diclofenac Sodium Generic 37 $1,134
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 111 $1,039
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 41 $377
Rifampin Generic 12 $264
Cephalexin Generic 43 $197
Sulfamethoxazole-Trimethoprim Sulfamethoxazole/Trimethoprim Brand 23 $185

The 10 drugs with the highest cost, of 15 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,934 Part D prescribers listed as Orthopedic Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 192 billing codes

Paid by Medicare

$322,247

Of which drugs: $34,959

Medicare patients

589

Average age 75

Services billed

6,762

370 women, 219 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Diabetes 35%
Ischemic heart disease 31%
Chronic kidney disease 31%
Depression 26%
Heart failure 24%
Atrial fibrillation 22%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, preservative-free, extended-release, microsphere formulation, 1 mg J3304 Office 16 864 $11,814
Hyaluronan or derivative, trivisc, for intra-articular injection, 1 mg J7329 Office 20 1,575 $8,806
Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg J0702 Office 86 186 $956
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 82 447 $302
Injection, ketorolac tromethamine, per 15 mg J1885 Office 11 44 $26

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

5 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
XIAFLEX
  • Endo USA, Inc. $46
$46 — —
EVENITY
  • Amgen Inc. $44
$44 — —
Prolia
  • Amgen Inc. $44
$44 — —
KRYSTEXXA
  • Amgen Inc. $27
$27 — —
Tymlos
  • Radius Health, Inc. $25
$25 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

102 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Orthopaedic Surgery in Tennessee

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record